Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Mesenchymal Precursor Cells

Cell therapy (Stem-cell derived) · developed by Mesoblast

Phase 2 Most advanced trial (none active)
MESO Developer
2 Registered trials

What is Mesenchymal Precursor Cells?

Mesenchymal Precursor Cells (MPC) are cells given by single intravenous infusion, in doses of 12.5 M or 25 M.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy (Stem-cell derived)
Therapy area
Cardiovascular, Endocrine
Developer
Mesoblast, Ltd. (MESO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01781390 Phase 2 Acute Myocardial Infarction Completed MESO
NCT01576328 Phase 1/2 Type 2 Diabetes Completed MESO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Myocardial InfarctionType 2 Diabetes

More from Mesoblast

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the MESO page.

Follow MESO, the company behind Mesenchymal Precursor Cells

See MESO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MESO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.